Novo Nordisk's Wegovy Pill Crushes Expectations: Time to Buy NVO?
💡 Key Takeaway
Novo Nordisk's new Wegovy pill is a massive success, expanding the GLP-1 market and potentially reversing its competitive lag against Eli Lilly, making its high-yield stock attractive for patient investors.
What Happened: Novo's Pill Is a Smash Hit
The battle for dominance in the lucrative GLP-1 weight-loss drug market took a surprising turn in early 2026. Novo Nordisk, which had lost its early lead due to supply issues with its Wegovy injection, launched a pill version of Wegovy. Consumer preference for pills over shots has proven decisive, leading to explosive growth.
The pill's performance has obliterated expectations. It generated 1.3 million prescriptions in its first quarter alone, and that number skyrocketed to 2 million just one month later when the company reported Q1 earnings. Crucially, the pill's success is not eating into sales of the injectable Wegovy, indicating it is successfully expanding the total market for these drugs.
This success comes despite Novo Nordisk warning that 2026 would be a tough year. The company faces patent expiration for Wegovy in India and agreed to price cuts in the U.S. market, both of which are pressuring sales. Management is betting that the pill's volume growth will eventually offset these price pressures.
While Eli Lilly remains the current market leader with its highly effective Mounjaro and Zepbound shots, Novo's pill appears to have an effectiveness edge over Lilly's own GLP-1 pill, giving Novo a potential marketing advantage in the oral drug segment.
Why It Matters: A Potential Game-Changer for NVO Stock
This matters because it could fundamentally alter the competitive narrative that has crushed Novo Nordisk's stock. Over the past three years, NVO shares are down 40% while Eli Lilly's are up over 150%, a direct reflection of Lilly's perceived dominance.
The pill's success proves Novo Nordisk is not out of the innovation race. It opens up a vast new patient population that prefers oral medication, potentially allowing Novo to recapture lost market share and drive long-term revenue growth that Wall Street had written off.
For income investors, the situation creates a unique opportunity. Novo Nordisk's stock decline has pushed its dividend yield to a historically high level near 3.9%, with a sustainable payout ratio around 40%. In contrast, Eli Lilly's yield is a minimal 0.6%.
The core investment question is whether the pill's strong early traction is a sign of a durable turnaround. If Novo can navigate its near-term headwinds in India and the U.S., the pill could be the catalyst that closes the performance gap with Eli Lilly. The risk is that in a fiercely competitive sector, Lilly could quickly respond with improved formulations.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Novo Nordisk (NVO) is a compelling buy for dividend-focused investors willing to weather near-term volatility for long-term potential.
The Wegovy pill's blistering start is a clear signal that Novo is back in the game, effectively expanding the total addressable market. Combined with a historically high and well-covered dividend yield, the stock's significant underperformance presents an attractive risk/reward balance as the company executes its transition.
What This Means for Me
